Genetic studies indicate that only a subset of genetic mechanisms regulating triglyceride-rich lipoproteins contribute to the risk of cardiovascular disease events, revealing new therapeutic targets.
Triglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower plasma triglycerides as a means to reduce CVD events. Genetic studies identified TGRL components and pathways involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs contribute to the risk of CVD events. This "omic" approach recently resulted in new targets for reducing CVD events.
“Our approach to patients with mild to moderate hypertriglyceridemia (fasting triglycerides ≥150 mg/dL to <880 mg/dL) involves a low fat and low glycemic index diet with caloric restriction in overweight patients, regular exercise, including aerobic and muscle strengthening, and guideline-directed management of major cardiovascular risk factors including intensive control of dysglycemia”
Rosenson et al. (Mon,) conducted a review in Atherosclerotic Cardiovascular Disease. Genetic studies indicate that only a subset of genetic mechanisms regulating triglyceride-rich lipoproteins contribute to the risk of cardiovascular disease events, revealing new therapeutic targets.